In addition, the outcomes for older individuals remain unsatisfactory, mainly due to the presence of comorbid conditions and, in particular, the genetic characteristics of the underlying disease [45].There is an urgent need to discover more potent inhibitors and to develop novel therapeutic approaches, including drug combination strategies, specifically for FLT3-ITD AML patients, in order to overcome current drug resistance. Here, FLT3 is linked to acute myeloid leukemia.